Results 91 to 100 of about 6,511 (194)

When can we stop cabergoline treatment in prolactinomas?

, 2003
Prolactinoma is the most common hormone-secreting pituitary adenoma. The approach to prolactinomas has changed in the past 25 years, thanks to treatment with dopamine agonists, which is characterized by a potent prolactin inhibitory effect, a tumor ...
A. Colao, G. Vitale, A. Di Sarno, G. Lombardi, F. Rota   +4 more
core   +1 more source

Comparative study of cabergoline and hydroxychloroquine to prevent ovarian hyperstimulation syndrome (OHSS) in PCOS patients: a pilot randomized clinical trial

Journal of Ovarian Research
Background This study compared the effectiveness of cabergoline and hydroxychloroquine in preventing ovarian hyperstimulation syndrome (OHSS) in patients with polycystic ovary syndrome (PCOS) undergoing controlled ovarian stimulation.
Elnaz Salari, Negar Ajabi Ardehjani, Ladan Kashani, Kasra Jafari, Ashraf Moini   +4 more
doaj   +1 more source

The Effect of Cabergoline on the Clinical and Immunological Aspects of Rheumatoid Arthritis Induced in Wistar Rats

Armaghane Danesh Bimonthly Journal, 2019
Background & aim: The anti-inflammatory effects of cabergoline have been documented in various studies. The purpose of the present study was to evaluate the effects of cabergoline administration (as a potent D2 agonist) on clinical aspects and immune ...
E Shaftaloud, SM Abtahi Froushani, N Delirezh   +2 more
doaj  

Long-term Effects of Cabergoline and Levodopa in Japanese Patients with Early Parkinson’s Disease: A 5-Year Prospective Study

Several international studies have suggested that treatment of early Parkinsonʼs disease (PD) with a dopamine agonist instead of levodopa delays the occurrence of motor complications.
Utsumi, Hiroya, Cabergoline as the Starting Treatment and its Long-term Effects (CASTLE) Study Group,   +1 more
core  

Iron molybdenum oxide-modified screen-printed electrode: Application for electrocatalytic oxidation of cabergoline

, 2020
This research designed a simplified, sensitive electro-chemical procedure to detect cabergoline by a means of a screen-priented electrode (SPE) modified with Fe2MoO6 magnetic nanocomposite (Fe2MoO6/SPE).
Van Le, Q., Jang, H.W., Shoaie, I.S., Aflatoonian, M.R., Khalilzadeh, M.A., Shokouhimehr, M., Beitollahi, H., Zhang, K., Aflatoonian, B., Tajik, S.   +9 more
core  

The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma

, 2014
PubMedID: 23945126Prolactinomas are common pituitary tumors that can cause gonadal dysfunction and infertility related to hyperprolactinemia. Dopamine agonists are the first-line treatment in these patients.
Yüksel B., Küpeli S., Kör Y., Zorludemir S., Yagci-Küpeli B., Gürbüz B.B., Gürbüz F.   +6 more
core   +1 more source

The treatment of prolactin microadenomas with cabergoline

, 2001
peer reviewedLa bromocriptine, un agoniste dopaminergique dérivé de l'ergot, a été mise au point peu de temps après la découverte de la prolactine et des prolactinomes vers 1970.
Beckers, Albert
core  

Stability of cabergoline in fox baits in laboratory and field conditions

, 2007
Cabergoline is a potent inhibitor of prolactin release and a potential fertility control agent for foxes. To understand how cabergoline could behave in baits deployed for fox control, we conducted laboratory and field trials to investigate the stability ...
Kirkwood, R (15510188), Brandon, S (15479636), Stuart McLean (14744008)   +2 more
core   +2 more sources

Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women.

, 2010
Context: Data concerning the safety for pregnancy of cabergoline treatment in hyperprolactinaemic women are still scarce. Objective: To exclude a higher than normal risk for miscarriage and congenital malformation in pregnancies initiated under ...
Hubinont, Corinne, Maiter, Dominique, Lebbe, Marie, Bernard, Pierre   +3 more
core   +1 more source

Use of Cabergoline in Prolactinomas

, 1998
Bromocriptine (BRC), the standard medication for prolactinomas, is effective in most cases but has a short half-life and occasional side effects. Cabergoline (CAB, Dostinex) is a potent D2-selective dopamine agonist, FDA-approved since12/1996 for ...
Victoria Pelak, MD; G. T. Liu, MD; S. L. Galetta, MD; N. Butler; A. Stein; L. Bolinger
core